Clinical Trial Update: Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of durvalumab and lurbinectedin for relapsed or refractory small cell lung cancer; the study is currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Zepzelca (lurbinectedin)

Snippet

Sponsor: Mayo Clinic | Conditions: Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING